This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Calcitriol ointment 3 microgram/g

Updated 2 Feb 2023 | Vitamin D and analogues


Ointment containing calcitriol

Drugs List

  • calcitriol 3microgram/g ointment
  • SILKIS 3microgram/g ointment
  • Therapeutic Indications


    Mild to moderately severe plaque psoriasis involving up to 35% body surface



    Apply to the psoriasis affected areas twice per day, once in the morning and once in the evening before retiring and after washing. A maximum of 30g of ointment should be used per day.

    Not more than 35% of the body surface should be exposed to daily treatment. There is limited clinical experience available in patients using this dosage over six weeks.


    Children aged 12 to 18 years (unlicensed)
    Apply twice per day, up to a maximum of 30g daily. Do not expose more than 35% of the body surface to calcitriol ointment per day.


    Children under 12 years
    Disorder of calcium metabolism
    Hepatic impairment
    Renal impairment

    Precautions and Warnings


    Advise patient to wash hands after use
    Avoid contact with eyes
    Avoid occlusive dressings
    No more than 35% of body surface area should be exposed to daily treatment
    Substances which stimulate absorption must not be added to the ointment
    Advise patient to seek medical advice if contact allergy occurs
    Discontinue treatment if severe irritation or contact allergy occurs
    Maximum 30 grams of ointment should be used per day

    Pregnancy and Lactation


    Use calcitriol with caution in pregnancy.

    At the time of writing there is limited published information regarding the use of calcitriol during pregnancy. The manufacturer states that research have shown developmental toxicity in animals.

    Calcitriol should only be applied in the smallest amount and when necessary. Monitor calcium and serum calcium concentration.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Calcitriol is contraindicated in breastfeeding.

    At the time of writing there is limited published information regarding the use of calcitriol during breastfeeding.

    The manufacturer states that calcitriol has been found in the milk of lactating dams.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Contact dermatitis
    Dry skin
    Exacerbation of psoriasis
    Hypersensitivity reactions
    Increase in plasma and urinary calcium
    Skin irritation


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: February 2017

    Reference Sources

    Summary of Product Characteristics: Silkis 3 micrograms per g ointment. Galderma (UK) Ltd. Revised July 2013.

    NICE Evidence Services Available at: Last accessed: 22 August 2017

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.